

Christine Hunt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5685906/publications.pdf>

Version: 2024-02-01

35
papers

2,497
citations

361413

20
h-index

377865

34
g-index

37
all docs

37
docs citations

37
times ranked

2716
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Case Definition and Phenotype Standardization in Drug-Induced Liver Injury. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 806-815. | 4.7 | 773 |
| 2 | Effect of age and gender on the activity of human hepatic CYP3A. <i>Biochemical Pharmacology</i> , 1992, 44, 275-283. | 4.4 | 393 |
| 3 | Clinical relevance of hepatitis B viral mutations. <i>Hepatology</i> , 2000, 31, 1037-1044. | 7.3 | 324 |
| 4 | Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial. <i>Hepatology</i> , 2000, 32, 135-138. | 7.3 | 162 |
| 5 | Drugs Associated with Hepatotoxicity and their Reporting Frequency of Liver Adverse Events in Vigibase, <i>Drug Safety</i> , 2010, 33, 503-522. | 3.2 | 142 |
| 6 | Effect of orthotopic liver transplantation on employment and health status. <i>Liver Transplantation</i> , 1996, 2, 148-153. | 1.8 | 63 |
| 7 | Drug-induced liver injury following positive drug rechallenge. <i>Regulatory Toxicology and Pharmacology</i> , 2009, 54, 84-90. | 2.7 | 54 |
| 8 | Drug rechallenge following drug-induced liver injury. <i>Hepatology</i> , 2017, 66, 646-654. | 7.3 | 50 |
| 9 | Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO Vigibase, <i>Regulatory Toxicology and Pharmacology</i> , 2015, 72, 481-490. | 2.7 | 46 |
| 10 | Age-related differences in reporting of drug-associated liver injury: Data-mining of WHO Safety Report Database. <i>Regulatory Toxicology and Pharmacology</i> , 2014, 70, 519-526. | 2.7 | 45 |
| 11 | Co-medications That Modulate Liver Injury and Repair Influence Clinical Outcome of Acetaminophen-Associated Liver Injury. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 882-888. | 4.4 | 38 |
| 12 | Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. <i>Pharmacogenomics</i> , 2013, 14, 541-554. | 1.3 | 37 |
| 13 | Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: A systematic review. <i>Hepatology</i> , 2010, 52, 2216-2222. | 7.3 | 33 |
| 14 | Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 268-278. | 3.7 | 33 |
| 15 | Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical record data. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 190-198. | 1.9 | 32 |
| 16 | <i>APOL1</i> Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program. <i>JAMA Internal Medicine</i> , 2022, 182, 386. | 5.1 | 31 |
| 17 | Interplay of gender, age and drug properties on reporting frequency of drug-induced liver injury. <i>Regulatory Toxicology and Pharmacology</i> , 2018, 94, 101-107. | 2.7 | 29 |
| 18 | Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2259-2266. | 2.3 | 26 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Children's liver chemistries vary with age and gender and require customized pediatric reference ranges. <i>Regulatory Toxicology and Pharmacology</i> , 2015, 73, 349-355. | 2.7 | 23 |
| 20 | Effect of postoperative complications on health and employment following liver transplantation. <i>Clinical Transplantation</i> , 1998, 12, 99-103. | 1.6 | 23 |
| 21 | Background incidence of liver chemistry abnormalities in a clinical trial population without underlying liver disease. <i>Regulatory Toxicology and Pharmacology</i> , 2008, 52, 85-88. | 2.7 | 21 |
| 22 | Regulation of rat hepatic cytochrome P450IIE1 in primary monolayer hepatocyte culture. <i>Xenobiotica</i> , 1991, 21, 1621-1631. | 1.1 | 19 |
| 23 | Comorbidities and Nonalcoholic Fatty Liver Disease: The Chicken, the Egg, or Both?. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2019, 36, 64-71. | 0.6 | 19 |
| 24 | Liver disease in pregnancy. <i>American Family Physician</i> , 1999, 59, 829-36. | 0.1 | 19 |
| 25 | A pre-marketing ALT signal predicts post-marketing liver safety. <i>Regulatory Toxicology and Pharmacology</i> , 2012, 63, 433-439. | 2.7 | 14 |
| 26 | Validation of Multivariate Outlier Detection Analyses Used to Identify Potential Drug-Induced Liver Injury in Clinical Trial Populations. <i>Drug Safety</i> , 2012, 35, 865-875. | 3.2 | 12 |
| 27 | A proposed modification to Hy's law and Edish criteria in oncology clinical trials using aggregated historical data. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 571-578. | 1.9 | 12 |
| 28 | Prevalence and incidence of liver enzyme elevations in a pooled oncology clinical trial cohort. <i>Regulatory Toxicology and Pharmacology</i> , 2016, 77, 257-262. | 2.7 | 9 |
| 29 | Expanding our toolkit to better identify drug-induced liver injury in electronic medical records. <i>Liver International</i> , 2018, 38, 585-587. | 3.9 | 4 |
| 30 | The evaluation of drug rechallenge: The casopitant Phase III program. <i>Regulatory Toxicology and Pharmacology</i> , 2010, 58, 539-543. | 2.7 | 3 |
| 31 | Proton-pump inhibitor use is not associated with severe COVID-19-related outcomes: a propensity score-weighted analysis of a national veteran cohort. <i>Gut</i> , 2022, 71, 1447-1450. | 12.1 | 3 |
| 32 | Hepatitis B Virus-related Care Quality in Patients With Hepatitis B/Human Immunodeficiency Virus Coinfection Versus Hepatitis B Mono-infection: A National Cohort Study. <i>Clinical Infectious Diseases</i> , 2022, 75, 1529-1536. | 5.8 | 3 |
| 33 | Implementation of Pharmacogenetic Testing Within the Veterans Health Administration From 2011 to 2013. <i>Military Medicine</i> , 2016, 181, 1375-1381. | 0.8 | 1 |
| 34 | Identifying and Treating Nonalcoholic Fatty Liver Disease. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2019, 36, 20-29. | 0.6 | 1 |
| 35 | Editorial: diabetes, obesity and clinical inertia—the recipe for advanced <sc>NASH</sc>. Authors'™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1221-1222. | 3.7 | 0 |